289 related articles for article (PubMed ID: 35957669)
1. LILRB4, an immune checkpoint on myeloid cells.
Yang T; Qian Y; Liang X; Wu J; Zou M; Deng M
Blood Sci; 2022 Apr; 4(2):49-56. PubMed ID: 35957669
[TBL] [Abstract][Full Text] [Related]
2. LILRB4 Checkpoint for Immunotherapy: Structure, Mechanism and Disease Targets.
Xiang Z; Yin X; Wei L; Peng M; Zhu Q; Lu X; Guo J; Zhang J; Li X; Zou Y
Biomolecules; 2024 Feb; 14(2):. PubMed ID: 38397424
[TBL] [Abstract][Full Text] [Related]
3. LILRB4, from the immune system to the disease target.
Liu J; Wu Q; Shi J; Guo W; Jiang X; Zhou B; Ren C
Am J Transl Res; 2020; 12(7):3149-3166. PubMed ID: 32774691
[TBL] [Abstract][Full Text] [Related]
4. Molecular regulatory mechanism of LILRB4 in the immune response.
Liu H; Yang J; Zhang J; Zhang P; Zhang M; Yang C; Liu L; Huang C; Wang W; Zhai Y; Yang J
Cent Eur J Immunol; 2023; 48(1):43-47. PubMed ID: 37206591
[TBL] [Abstract][Full Text] [Related]
5. Leukocyte Ig-like receptor B4 (LILRB4) is a potent inhibitor of FcgammaRI-mediated monocyte activation via dephosphorylation of multiple kinases.
Lu HK; Rentero C; Raftery MJ; Borges L; Bryant K; Tedla N
J Biol Chem; 2009 Dec; 284(50):34839-48. PubMed ID: 19833736
[TBL] [Abstract][Full Text] [Related]
6. LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs.
Su MT; Kumata S; Endo S; Okada Y; Takai T
Oncoimmunology; 2022; 11(1):2060907. PubMed ID: 35402083
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of leukocyte Ig-like receptor LILRB4 (ILT3/LIR-5/CD85k): a myeloid inhibitory receptor involved in immune tolerance.
Cheng H; Mohammed F; Nam G; Chen Y; Qi J; Garner LI; Allen RL; Yan J; Willcox BE; Gao GF
J Biol Chem; 2011 May; 286(20):18013-25. PubMed ID: 21454581
[TBL] [Abstract][Full Text] [Related]
8. Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation.
Churchill HRO; Fuda FS; Xu J; Deng M; Zhang CC; An Z; Zhang N; Chen P; Bergstrom C; Kansagra A; Collins R; John S; Koduru P; Chen W
Cytometry B Clin Cytom; 2021 Jul; 100(4):476-487. PubMed ID: 32918786
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of pathologic inflammation by leukocyte Ig-like receptor B4 and related inhibitory receptors.
Katz HR
Immunol Rev; 2007 Jun; 217():222-30. PubMed ID: 17498062
[TBL] [Abstract][Full Text] [Related]
10. Fc gamma receptors promote antibody-induced LILRB4 internalization and immune regulation of monocytic AML.
Morse JW; Gui X; Deng M; Huang R; Ye X; Zhao P; Fan X; Xiong W; Zhang C; Zhang N; An Z
Antib Ther; 2024 Jan; 7(1):13-27. PubMed ID: 38235377
[TBL] [Abstract][Full Text] [Related]
11. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration.
Deng M; Gui X; Kim J; Xie L; Chen W; Li Z; He L; Chen Y; Chen H; Luo W; Lu Z; Xie J; Churchill H; Xu Y; Zhou Z; Wu G; Yu C; John S; Hirayasu K; Nguyen N; Liu X; Huang F; Li L; Deng H; Tang H; Sadek AH; Zhang L; Huang T; Zou Y; Chen B; Zhu H; Arase H; Xia N; Jiang Y; Collins R; You MJ; Homsi J; Unni N; Lewis C; Chen GQ; Fu YX; Liao XC; An Z; Zheng J; Zhang N; Zhang CC
Nature; 2018 Oct; 562(7728):605-609. PubMed ID: 30333625
[TBL] [Abstract][Full Text] [Related]
12. Fibronectin on target cells attenuates natural cytotoxicity of NK cells via myeloid immune checkpoint ILT3/LILRB4/gp49B.
Itagaki F; Nakatsuka K; Sakai H; Endo S; Su MT; Takai T
Int Immunol; 2023 Jul; 35(7):339-348. PubMed ID: 37083755
[TBL] [Abstract][Full Text] [Related]
13. NK cells require immune checkpoint receptor LILRB4/gp49B to control neurotropic Zika virus infections in mice.
Lee HN; Manangeeswaran M; Lewkowicz AP; Engel K; Chowdhury M; Garige M; Eckhaus MA; Sourbier C; Ireland DD; Verthelyi D
JCI Insight; 2022 Feb; 7(3):. PubMed ID: 35132958
[TBL] [Abstract][Full Text] [Related]
14. LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells.
Li Z; Deng M; Huang F; Jin C; Sun S; Chen H; Liu X; He L; Sadek AH; Zhang CC
Cell Mol Immunol; 2020 Mar; 17(3):272-282. PubMed ID: 31700117
[TBL] [Abstract][Full Text] [Related]
15. Leukocyte immunoglobulin-like receptor B4 deficiency exacerbates acute lung injury via NF-κB signaling in bone marrow-derived macrophages.
Qiu T; Zhou J; Wang T; Chen Z; Ma X; Zhang L; Zou J
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31138763
[TBL] [Abstract][Full Text] [Related]
16. Co-localization of Fibronectin Receptors LILRB4/gp49B and Integrin on Dendritic Cell Surface.
Takahashi N; Itoi S; Su MT; Endo S; Takai T
Tohoku J Exp Med; 2022 Jun; 257(3):171-180. PubMed ID: 35691913
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the Leucocyte Immunoglobulin-like Receptor B4 (
Kretzschmar F; Piecha R; Jahn J; Potru PS; Spittau B
Biology (Basel); 2021 Dec; 10(12):. PubMed ID: 34943215
[TBL] [Abstract][Full Text] [Related]
18. Leukocyte immunoglobulin-like receptor B4 protects against cardiac hypertrophy via SHP-2-dependent inhibition of the NF-κB pathway.
Zhou H; Li N; Yuan Y; Jin YG; Wu Q; Yan L; Bian ZY; Deng W; Shen DF; Li H; Tang QZ
J Mol Med (Berl); 2020 May; 98(5):691-705. PubMed ID: 32280997
[TBL] [Abstract][Full Text] [Related]
19. Biomimetic design of inhibitors of immune checkpoint LILRB4.
Chao Y; Zhang L
Biophys Chem; 2022 Mar; 282():106746. PubMed ID: 34963077
[TBL] [Abstract][Full Text] [Related]
20. Hepatic leukocyte immunoglobulin-like receptor B4 (LILRB4) attenuates nonalcoholic fatty liver disease via SHP1-TRAF6 pathway.
Lu Y; Jiang Z; Dai H; Miao R; Shu J; Gu H; Liu X; Huang Z; Yang G; Chen AF; Yuan H; Li Y; Cai J
Hepatology; 2018 Apr; 67(4):1303-1319. PubMed ID: 29091299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
